Abo Bibliothek: Guest
Critical Reviews™ in Neurobiology

Erscheint 3 Ausgaben pro Jahr

ISSN Druckformat: 0892-0915

ISSN Online: 2375-0014

SJR: 0.121

Schizophrenia and Glutamatergic Transmission

Volumen 12, Ausgabe 1-2, 1998, pp. 21-36
DOI: 10.1615/CritRevNeurobiol.v12.i1-2.20
Get accessGet access

ABSTRAKT

Schizophrenia is a human brain disease with well-defined symptoms and a lifelong disease course, but without a current biological explanation. Several observations implicate brain glutamatergic abnormalities in the pathophysiology of this illness. This evidence includes both human neurochemical and clinical pharmacologic data. Furthermore the psychotomimetic action of phencyclidine, the noncompetitive NMDA-sensitive glutamate receptor antagonist, suggests the association between human psychosis and NMDA receptor blockade. This paper reviews basic aspects of glutamatergic transmission in animal and human brain with particular attention to its putative role in schizophrenia. Consideration is given to other glutamate-related human brain diseases and their purported mechanisms. Evidence of glutamatergic abnormalities in schizophrenia is critically reviewed, including data using postmortem neurochemistry, in vivo human brain imaging, clinical pharmacology, and animal models. The current theoretical formulations based on these studies are articulated. We propose a "working" glutamate hypothesis of schizophrenia which postulates a diminished glutamatergic transmission in the hippocampal glutamate-mediated efferent pathways and cerebral dysfunction in the hippocampus and its target areas, especially the anterior cingulate cortex. Considerable work remains to be done in this area to formulate and test a comprehensive hypothesis.

REFERENZIERT VON
  1. Doi Nagafumi, Hoshi Yoko, Itokawa Masanari, Yoshikawa Takeo, Ichikawa Tomoe, Arai Makoto, Usui Chie, Tachikawa Hirokazu, Paradox of schizophrenia genetics: is a paradigm shift occurring?, Behavioral and Brain Functions, 8, 1, 2012. Crossref

  2. Dwyer Donard S, Lu Xiao-Hong, III Arthur M Freeman, Neuronal glucose metabolism and schizophrenia: therapeutic prospects?, Expert Review of Neurotherapeutics, 3, 1, 2003. Crossref

  3. Koga Eiko, Momiyama Toshihiko, Presynaptic dopamine D 2 ‐like receptors inhibit excitatory transmission onto rat ventral tegmental dopaminergic neurones , The Journal of Physiology, 523, 1, 2000. Crossref

  4. Schaus John M., Bymaster Frank P., , 33, 1998. Crossref

  5. Hockberger Robert S., Richards John R., Thought Disorders, in Rosen's Emergency Medicine – Concepts and Clinical Practice, 2010. Crossref

  6. Traverso Luis M., Ruiz Gabriel, De la Casa Luis G., Effect of the NMDA antagonist MK-801 on latent inhibition of fear conditioning, Pharmacology Biochemistry and Behavior, 102, 4, 2012. Crossref

  7. Holcomb Henry H, Lahti Adrienne C, Medoff Deborah R, Cullen Tom, Tamminga Carol A, Effects of Noncompetitive NMDA Receptor Blockade on Anterior Cingulate Cerebral Blood Flow in Volunteers with Schizophrenia, Neuropsychopharmacology, 30, 12, 2005. Crossref

  8. Fowler Jill H., Whalley Katherine, Murray Tracey, O'Neill Michael J., McCulloch James, The AMPA Receptor Potentiator LY404187 Increases Cerebral Glucose Utilization and c-fos Expression in the Rat, Journal of Cerebral Blood Flow & Metabolism, 24, 10, 2004. Crossref

  9. Singh B., Recognition and optimal management of schizophrenia and related psychoses, Internal Medicine Journal, 35, 7, 2005. Crossref

  10. Bagorda F., Teuchert-Noodt G., Lehmann K., Isolation rearing or methamphetamine traumatisation induce a “dysconnection” of prefrontal efferents in gerbils: implications for schizophrenia, Journal of Neural Transmission, 113, 3, 2006. Crossref

  11. Lees Gordon J., Pharmacology of AMPA/Kainate Receptor Ligands and Their Therapeutic Potential in Neurological and Psychiatric Disorders, Drugs, 59, 1, 2000. Crossref

  12. Tamminga C. A., Southcott S., Sacco C., Wagner A. D., Ghose S., Glutamate Dysfunction in Hippocampus: Relevance of Dentate Gyrus and CA3 Signaling, Schizophrenia Bulletin, 38, 5, 2012. Crossref

  13. Schwarz Emanuel, Bahn Sabine, Cerebrospinal fluid: identification of diagnostic markers for schizophrenia, Expert Review of Molecular Diagnostics, 8, 2, 2008. Crossref

  14. Stone Trevor W., Stoy Nicholas, Darlington L. Gail, An expanding range of targets for kynurenine metabolites of tryptophan, Trends in Pharmacological Sciences, 34, 2, 2013. Crossref

  15. Tarazi Frank I, Neill Jo C, The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania, Expert Opinion on Drug Discovery, 8, 1, 2013. Crossref

  16. Paus Sebastian, Rietschel Marcella, Schulze Thomas G., Ohlraun Stephanie, Diaconu Carmen C., Den Bogaert Ann Van, Maier Wolfgang, Propping Peter, Cichon Sven, N??then Markus M., Systematic screening for mutations in the human N-methyl-D-aspartate receptor 1 gene in schizophrenic patients from the German population, Psychiatric Genetics, 14, 4, 2004. Crossref

  17. Martres Marie-Pascale, Les systèmes de neurotransmission centraux et leur implication dans les psychoses, Therapies, 63, 3, 2008. Crossref

  18. Ceresoli-Borroni G., Rassoulpour A., Wu H.-Q., Guidetti P., Schwarcz R., Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain, Journal of Neural Transmission, 113, 10, 2006. Crossref

  19. Ishiguro Hiroki, Saito Toshikazu, Shibuya Haruo, Toru Michio, Arinami Tadao, Mutation and association analysis of the Fyn kinase gene with alcoholism and schizophrenia, American Journal of Medical Genetics, 96, 6, 2000. Crossref

  20. Gao Xue-Min, Hashimoto Takeshi, Tamminga Carol A., Phencyclidine (PCP) and dizocilpine (MK801) exert time-dependent effects on the expression of immediate early genes in rat brain, Synapse, 29, 1, 1998. Crossref

  21. Vinogradova O.S., Hippocampus as comparator: Role of the two input and two output systems of the hippocampus in selection and registration of information, Hippocampus, 11, 5, 2001. Crossref

  22. MIYAMOTO Yoshiaki, NABESHIMA Toshitaka, Analysis of neuronal functions in mice lacking the NMDA receptor .EPSILON.1 subunit., Folia Pharmacologica Japonica, 119, 6, 2002. Crossref

  23. Zhang Lin, Shirayama Yukihiko, Iyo Masaomi, Hashimoto Kenji, Minocycline Attenuates Hyperlocomotion and Prepulse Inhibition Deficits in Mice after Administration of the NMDA Receptor Antagonist Dizocilpine, Neuropsychopharmacology, 32, 9, 2007. Crossref

  24. Barros Virginia G., Berger María A., Martijena Irene D., Sarchi María I., Pérez Adriana A., Molina Victor A., Tarazi Frank I., Antonelli Marta C., Early adoption modifies the effects of prenatal stress on dopamine and glutamate receptors in adult rat brain, Journal of Neuroscience Research, 76, 4, 2004. Crossref

  25. Hikichi Hirohiko, Kaku Ayaka, Karasawa Jun-ichi, Chaki Shigeyuki, Stimulation of Metabotropic Glutamate (mGlu) 2 Receptor and Blockade of mGlu1 Receptor Improve Social Memory Impairment Elicited by MK-801 in Rats, Journal of Pharmacological Sciences, 122, 1, 2013. Crossref

  26. Hickey Andrea J., Reynolds James N., Beninger Richard J., Post-weaning social isolation and subchronic NMDA glutamate receptor blockade: Effects on locomotor activity and GABA signaling in the rat suggest independent mechanisms, Pharmacology Biochemistry and Behavior, 101, 2, 2012. Crossref

  27. Benes Francine M., Neural Circuitry Models of Schizophrenia: Is it Dopamine, GABA, Glutamate, or Something Else?, Biological Psychiatry, 65, 12, 2009. Crossref

  28. Henson Maile A., Roberts Adam C., Salimi Kayvon, Vadlamudi Swarooparani, Hamer Robert M., Gilmore John H., Jarskog L. Fredrik, Philpot Benjamin D., Developmental Regulation of the NMDA Receptor Subunits, NR3A and NR1, in Human Prefrontal Cortex, Cerebral Cortex, 18, 11, 2008. Crossref

  29. Berretta Sabina, Lange Nicholas, Bhattacharyya Sujoy, Sebro Ronnie, Garces Jessica, Benes Francine M., Long-term effects of amygdala GABA receptor blockade on specific subpopulations of hippocampal interneurons, Hippocampus, 14, 7, 2004. Crossref

  30. Basta-Kaim A., Fijał K., Budziszewska B., Regulska M., Leśkiewicz M., Kubera M., Gołembiowska K., Lasoń W., Wędzony K., Prenatal lipopolysaccharide treatment enhances MK-801-induced psychotomimetic effects in rats, Pharmacology Biochemistry and Behavior, 98, 2, 2011. Crossref

  31. Esiri Margaret, Crow Tim, Psychiatric diseases, in Greenfield's Neuropathology Eighth Edition. 2 Volume Set and DVD, 2008. Crossref

  32. Moy Sheryl S., Perez Antonio, Koller Beverly H., Duncan Gary E., Amphetamine-induced disruption of prepulse inhibition in mice with reduced NMDA receptor function, Brain Research, 1089, 1, 2006. Crossref

  33. Papp Andras, Juranyi Zsolt, Nagymajtenyi Laszlo, Matyus Peter, Harsing Laszlo G., The synaptic and nonsynaptic glycine transporter type-1 inhibitors Org-24461 and NFPS alter single neuron firing rate in the rat dorsal raphe nucleus, Neurochemistry International, 52, 1-2, 2008. Crossref

  34. Rezvani Amir, Involvement of the NMDA System in Learning and Memory, in Animal Models of Cognitive Impairment, 20064835, 2006. Crossref

  35. Lin Chi-Ying, Sawa Akira, Jaaro-Peled Hanna, Better understanding of mechanisms of schizophrenia and bipolar disorder: From human gene expression profiles to mouse models, Neurobiology of Disease, 45, 1, 2012. Crossref

  36. Fukumoto Makoto, Iwata Masaaki, Shinbori Chiko, Hazama Gen-i, Shirayama Yukihiko, Kawahara Ryuzou, Effects of acute administration of methamphetamine on Narp mRNA in rat brain, Addiction Biology, 10, 3, 2005. Crossref

  37. Yanagi Masaya, Southcott Sarah, Lister Jacob, Tamminga Carol A., Animal Models of Schizophrenia, in Animal Models of Molecular Pathology, 105, 2012. Crossref

  38. Pantazopoulos Harry, Stone David, Walsh John, Benes Francine M., Differences in the cellular distribution of D1 receptor mRNA in the hippocampus of bipolars and schizophrenics, Synapse, 54, 3, 2004. Crossref

  39. Gallinat Jürgen, Götz Thomas, Kalus Peter, Bajbouj Malek, Sander Thomas, Winterer Georg, Genetic Variations of the NR3A Subunit of the NMDA Receptor Modulate Prefrontal Cerebral Activity in Humans, Journal of Cognitive Neuroscience, 19, 1, 2007. Crossref

  40. Cohen Martin, Solowij Nadia, Carr Vaughan, Cannabis, Cannabinoids and Schizophrenia: Integration of the Evidence, Australian & New Zealand Journal of Psychiatry, 42, 5, 2008. Crossref

  41. Wu H.-Q., Okuyama M., Kajii Y., Pocivavsek A., Bruno J. P., Schwarcz R., Targeting Kynurenine Aminotransferase II in Psychiatric Diseases: Promising Effects of an Orally Active Enzyme Inhibitor, Schizophrenia Bulletin, 40, Suppl 2, 2014. Crossref

  42. Gray Laura, van den Buuse Maarten, Scarr Elizabeth, Dean Brian, Hannan Anthony J., Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-d-aspartic acid receptor up-regulation, The International Journal of Neuropsychopharmacology, 12, 01, 2009. Crossref

  43. Flores Cecilia, Wen Xianglan, Labelle-Dumais Cassandre, Kolb Bryan, Chronic phencyclidine treatment increases dendritic spine density in prefrontal cortex and nucleus accumbens neurons, Synapse, 61, 12, 2007. Crossref

  44. Gaisler-Salomon I., Diamant L., Rubin C., Weiner I., Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered, Psychopharmacology, 196, 2, 2008. Crossref

  45. Stone Trevor W, Kynurenic acid antagonists and kynurenine pathway inhibitors, Expert Opinion on Investigational Drugs, 10, 4, 2001. Crossref

  46. Amitai Nurith, Kuczenski Ronald, Behrens M. Margarita, Markou Athina, Repeated phencyclidine administration alters glutamate release and decreases GABA markers in the prefrontal cortex of rats, Neuropharmacology, 62, 3, 2012. Crossref

  47. Tamminga C, The limbic cortex in schizophrenia: focus on the anterior cingulate, Brain Research Reviews, 31, 2-3, 2000. Crossref

  48. Lazarewicz Maciej T., Ehrlichman Richard S., Maxwell Christina R., Gandal Michael J., Finkel Leif H., Siegel Steven J., Ketamine Modulates Theta and Gamma Oscillations, Journal of Cognitive Neuroscience, 22, 7, 2010. Crossref

  49. Camara Marie lou, Corrigan Frances, Jaehne Emily J, Jawahar Magdalene C, Anscomb Helen, Baune Bernhard T, Effects of Centrally Administered Etanercept on Behavior, Microglia, and Astrocytes in Mice Following a Peripheral Immune Challenge, Neuropsychopharmacology, 40, 2, 2015. Crossref

  50. Choi Changho, Dimitrov Ivan, Douglas Deborah, Zhao Chenguang, Hawesa Halima, Ghose Subroto, Tamminga Carol A., In vivo detection of serine in the human brain by proton magnetic resonance spectroscopy (1 H-MRS) at 7 Tesla, Magnetic Resonance in Medicine, 62, 4, 2009. Crossref

  51. O'Neill Michael J., Murray Tracey K., Clay Michael P., Lindstrom Terry, Yang Charles R., Nisenbaum Eric S., LY503430: Pharmacology, Pharmacokinetics, and Effects in Rodent Models of Parkinson's Disease, CNS Drug Reviews, 11, 1, 2006. Crossref

  52. Schizophrenia, in Wiley Handbook of Current and Emerging Drug Therapies, 2007. Crossref

  53. Moghaddam Bita, Homayoun Houman, Dopamine and Glutamate Hypotheses of Schizophrenia, in Handbook of Contemporary Neuropharmacology, 2007. Crossref

  54. Lovelace Jonathan W, Vieira Philip A, Corches Alex, Mackie Ken, Korzus Edward, Impaired Fear Memory Specificity Associated with Deficient Endocannabinoid-Dependent Long-Term Plasticity, Neuropsychopharmacology, 39, 7, 2014. Crossref

  55. Tomitaka Shinichiro, Tomitaka Midori, Tolliver Bryan K., Sharp Frank R., Bilateral blockade of NMDA receptors in anterior thalamus by dizocilpine (MK-801) injures pyramidal neurons in rat retrosplenial cortex, European Journal of Neuroscience, 12, 4, 2000. Crossref

  56. Gray Laura, McOmish Caitlin E., Scarr Elizabeth, Dean Brian, Hannan Anthony J., Sensitivity to MK-801 in phospholipase C-β1 knockout mice reveals a specific NMDA receptor deficit, The International Journal of Neuropsychopharmacology, 12, 07, 2009. Crossref

  57. Hackler E.A., Byun N.E., Jones C.K., Williams J.M., Baheza R., Sengupta S., Grier M.D., Avison M., Conn P.J., Gore J.C., Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation, Neuroscience, 168, 1, 2010. Crossref

  58. Quirk Jennifer C., Nisenbaum Eric S., LY404187: A Novel Positive Allosteric Modulator of AMPA Receptors, CNS Drug Reviews, 8, 3, 2006. Crossref

  59. Tarazi Frank I., Baldessarini Ross J., Regional localization of dopamine and ionotropic glutamate receptor subtypes in striatolimbic brain regions, Journal of Neuroscience Research, 55, 4, 1999. Crossref

  60. Leewanich Pathama, Tohda Michihisa, Takayama Hiromitsu, Sophasan Samaisukh, Watanabe Hiroshi, Matsumoto Kinzo, Corymine Potentiates NMDA-Induced Currents in Xenopus Oocytes Expressing NR1a/NR2B Glutamate Receptors, Journal of Pharmacological Sciences, 98, 1, 2005. Crossref

  61. Hinterhoelzl Josef K., Salimi Kayvon, Humpel Christian, Singewald Nicolas, Adlassnig Christine, Fischer-Colbrie Reiner, Fleischhacker Wolfgang W., Marksteiner Josef, Differential effects of phencyclidine application on secretogranin II expression in organotypic slices of rat prefrontal cortex, Journal of Neurochemistry, 87, 1, 2003. Crossref

  62. Talpos John C., Aerts Nancy, Fellini Laetitia, Steckler Thomas, A touch-screen based paired-associates learning (PAL) task for the rat may provide a translatable pharmacological model of human cognitive impairment, Pharmacology Biochemistry and Behavior, 122, 2014. Crossref

  63. Pickering Chris, Ericson Mia, Söderpalm Bo, Chronic Phencyclidine Increases Synapsin-1 and Synaptic Adaptation Proteins in the Medial Prefrontal Cortex, ISRN Psychiatry, 2013, 2013. Crossref

  64. Vogels Tim P, Abbott L F, Gating multiple signals through detailed balance of excitation and inhibition in spiking networks, Nature Neuroscience, 12, 4, 2009. Crossref

  65. Nakazawa Kazu, Zsiros Veronika, Jiang Zhihong, Nakao Kazuhito, Kolata Stefan, Zhang Shuqin, Belforte Juan E., GABAergic interneuron origin of schizophrenia pathophysiology, Neuropharmacology, 62, 3, 2012. Crossref

  66. Bujas-Bobanovic M, Bird D C, Robertson H A, Dursun S M, Blockade of phencyclidine-induced effects by a nitric oxide donor, British Journal of Pharmacology, 130, 5, 2000. Crossref

  67. Cyr , Ghribi , Di Paolo , Regional and Selective Effects of Oestradiol and Progesterone on NMDA and AMPA Receptors in the Rat Brain, Journal of Neuroendocrinology, 12, 5, 2001. Crossref

  68. WEST ANTHONY R., FLORESCO STAN B., CHARARA ALI, ROSENKRANZ J. AMIEL, GRACE ANTHONY A., Electrophysiological Interactions between Striatal Glutamatergic and Dopaminergic Systems, Annals of the New York Academy of Sciences, 1003, 1, 2003. Crossref

  69. Nakazato Atsuro, Okuyama Shigeru, Recent advances in novel atypical antipsychotic agents: potential therapeutic agents for the treatment of schizophrenia, Expert Opinion on Therapeutic Patents, 10, 1, 2000. Crossref

  70. HARRISON PAUL J., LAW AMANDA J., EASTWOOD SHARON L., Glutamate Receptors and Transporters in the Hippocampus in Schizophrenia, Annals of the New York Academy of Sciences, 1003, 1, 2003. Crossref

  71. STEFANI MARK R., MOGHADDAM BITA, Distinct Contributions of Glutamate Receptor Subtypes to Cognitive Set-Shifting Abilities in the Rat, Annals of the New York Academy of Sciences, 1003, 1, 2003. Crossref

  72. López-Gil Xavier, Babot Zoila, Amargós-Bosch Mercè, Suñol Cristina, Artigas Francesc, Adell Albert, Clozapine and Haloperidol Differently Suppress the MK-801-Increased Glutamatergic and Serotonergic Transmission in the Medial Prefrontal Cortex of the Rat, Neuropsychopharmacology, 32, 10, 2007. Crossref

  73. Nagy Katalin, Marko Bernadett, Zsilla Gabriella, Matyus Peter, Pallagi Katalin, Szabo Geza, Juranyi Zsolt, Barkoczy Jozsef, Levay Gyorgy, Harsing Laszlo G., Alterations in Brain Extracellular Dopamine and Glycine Levels Following Combined Administration of the Glycine Transporter Type-1 Inhibitor Org-24461 and Risperidone, Neurochemical Research, 35, 12, 2010. Crossref

  74. Locklear M.N., Bhamidipaty S., Kritzer M.F., Local N-methyl-d-aspartate receptor antagonism in the prefrontal cortex attenuates spatial cognitive deficits induced by gonadectomy in adult male rats, Neuroscience, 288, 2015. Crossref

  75. McCormick Laurie M., Boles Ponto Laura L., Pierson Ron K., Johnson Hans J., Magnotta Vincent, Brumm Michael C., Metabolic Correlates of Antidepressant and Antipsychotic Response in Patients With Psychotic Depression Undergoing Electroconvulsive Therapy, The Journal of ECT, 23, 4, 2007. Crossref

  76. TAMMINGA CAROL A., LAHTI ADRIENNE C., MEDOFF DEBORAH R., GAO XUE-MIN, HOLCOMB HENRY H., Evaluating Glutamatergic Transmission in Schizophrenia, Annals of the New York Academy of Sciences, 1003, 1, 2003. Crossref

  77. Arad Michal, Weiner Ina, Sex-Dependent Antipsychotic Capacity of 17β-Estradiol in the Latent Inhibition Model: A Typical Antipsychotic Drug in Both Sexes, Atypical Antipsychotic Drug in Males, Neuropsychopharmacology, 35, 11, 2010. Crossref

  78. MOGHADDAM BITA, JACKSON MARK E., Glutamatergic Animal Models of Schizophrenia, Annals of the New York Academy of Sciences, 1003, 1, 2003. Crossref

  79. Citri Ami, Malenka Robert C, Synaptic Plasticity: Multiple Forms, Functions, and Mechanisms, Neuropsychopharmacology, 33, 1, 2008. Crossref

  80. Gasbarri Antonella, Pompili Assunta, Involvement of Glutamate in Learning and Memory, in Identification of Neural Markers Accompanying Memory, 2014. Crossref

  81. Schuitz Susan K, Andreasen Nancy C, Schizophrenia, The Lancet, 353, 9162, 1999. Crossref

  82. Deutsch Stephen I, Rosse Richard B, Billingslea Eddie N, Bellack Alan S, Mastropaolo John, Modulation of MK-801-elicited mouse popping behavior by galantamine is complex and dose-dependent, Life Sciences, 73, 18, 2003. Crossref

  83. Tsou Jonathan Y., Intervention, causal reasoning, and the neurobiology of mental disorders: Pharmacological drugs as experimental instruments, Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences, 43, 2, 2012. Crossref

  84. Wong Albert Hung Choy, Van Tol Hubert H.M., Schizophrenia: from phenomenology to neurobiology, Neuroscience & Biobehavioral Reviews, 27, 3, 2003. Crossref

  85. Elsworth J. D., Groman S. M., Jentsch J. D., Leranth C., Redmond D. E., Kim J. D., Diano S., Roth R. H., Primate Phencyclidine Model of Schizophrenia: Sex-Specific Effects on Cognition, Brain Derived Neurotrophic Factor, Spine Synapses, and Dopamine Turnover in Prefrontal Cortex, International Journal of Neuropsychopharmacology, 18, 6, 2015. Crossref

  86. Ingason A, Giegling I, Hartmann A M, Genius J, Konte B, Friedl M, Ripke S, Sullivan P F, St. Clair D, Collier D A, O'Donovan M C, Mirnics K, Rujescu D, Expression analysis in a rat psychosis model identifies novel candidate genes validated in a large case–control sample of schizophrenia, Translational Psychiatry, 5, 10, 2015. Crossref

  87. Koenig James I., Schizophrenia: A unique translational opportunity in behavioral neuroendocrinology, Hormones and Behavior, 50, 4, 2006. Crossref

  88. Stefani Mark Renato, Moghaddam Bita, Transient N-methyl-D-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia, Biological Psychiatry, 57, 4, 2005. Crossref

  89. Boyer Patrice, Phillips Jennifer L., Rousseau François L., Ilivitsky Susan, Hippocampal abnormalities and memory deficits: New evidence of a strong pathophysiological link in schizophrenia, Brain Research Reviews, 54, 1, 2007. Crossref

  90. Hajszan Tibor, Leranth Csaba, Roth Robert H., Subchronic Phencyclidine Treatment Decreases the Number of Dendritic Spine Synapses in the Rat Prefrontal Cortex, Biological Psychiatry, 60, 6, 2006. Crossref

  91. Zhang Boyu, Yuan Yanbo, Jia Yanbin, Yu Xin, Xu Qi, Shen Yucun, Shen Yan, An association study between polymorphisms in five genes in glutamate and GABA pathway and paranoid schizophrenia, European Psychiatry, 20, 1, 2005. Crossref

  92. Benes Francine M, Vincent Stephen L, Todtenkopf Mark, The density of pyramidal and nonpyramidal neurons in anterior cingulate cortex of schizophrenic and bipolar subjects, Biological Psychiatry, 50, 6, 2001. Crossref

  93. Talpos John, Aerts Nancy, Waddell Jason, Steckler Thomas, MK-801 and amphetamine result in dissociable profiles of cognitive impairment in a rodent paired associates learning task with relevance for schizophrenia, Psychopharmacology, 232, 21-22, 2015. Crossref

  94. Swayze Richard D., Lisé Marie-France, Levinson Joshua N., Phillips Anthony, El-Husseini Alaa, Modulation of dopamine mediated phosphorylation of AMPA receptors by PSD-95 and AKAP79/150, Neuropharmacology, 47, 5, 2004. Crossref

  95. Phillips Dean, Sonnenberg Jennifer, Arai Amy C, Vaswani Rishi, Krutzik Peter O, Kleisli Thomas, Kessler Markus, Granger Richard, Lynch Gary, Richard Chamberlin A, 5′-Alkyl-benzothiadiazides: A New Subgroup of AMPA Receptor Modulators with Improved Affinity, Bioorganic & Medicinal Chemistry, 10, 5, 2002. Crossref

  96. Goudie Andrew J, Smith Judith A, Discriminative Stimulus Properties of Antipsychotics, Pharmacology Biochemistry and Behavior, 64, 2, 1999. Crossref

  97. Castner Stacy A., Williams Graham V., Tuning the engine of cognition: A focus on NMDA/D1 receptor interactions in prefrontal cortex, Brain and Cognition, 63, 2, 2007. Crossref

  98. Wang Xun, Gu Zhenglin, Zhong Ping, Chen Guojun, Feng Jian, Yan Zhen, Aberrant regulation of NMDA receptors by dopamine D4 signaling in rats after phencyclidine exposure, Molecular and Cellular Neuroscience, 31, 1, 2006. Crossref

  99. Koch Michael, Schmiedt-Fehr Christina, Mathes Birgit, Neuropharmacology of altered brain oscillations in schizophrenia, International Journal of Psychophysiology, 103, 2016. Crossref

  100. Hashimoto Kenji, Fujimura Masatake, Yamagami Keiji, Dizocilpine-induced neuropathological changes in rat retrosplenial cortex are reversed by subsequent clozapine treatment, Life Sciences, 66, 12, 2000. Crossref

  101. Jadi Monika P., Behrens M. Margarita, Sejnowski Terrence J., Abnormal Gamma Oscillations in N-Methyl-D-Aspartate Receptor Hypofunction Models of Schizophrenia, Biological Psychiatry, 79, 9, 2016. Crossref

  102. Heresco-Levy Uriel, Ermilov Marina, Lichtenberg Pesah, Bar Gali, Javitt Daniel C, High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia, Biological Psychiatry, 55, 2, 2004. Crossref

  103. Deutsch Stephen I, Rosse Richard B, Billingslea Eddie N, Bellack Alan S, Mastropaolo John, Topiramate antagonizes MK-801 in an animal model of schizophrenia, European Journal of Pharmacology, 449, 1-2, 2002. Crossref

  104. Danbolt Niels C, Glutamate uptake, Progress in Neurobiology, 65, 1, 2001. Crossref

  105. Magri Chiara, Gardella Rita, Valsecchi Paolo, Barlati Stefano Davide, Guizzetti Luca, Imperadori Laura, Bonvicini Cristian, Tura Gian Battista, Gennarelli Massimo, Sacchetti Emilio, Barlati Sergio, Study on GRIA2, GRIA3 and GRIA4 genes highlights a positive association between schizophrenia and GRIA3 in female patients, American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 147B, 6, 2008. Crossref

  106. Álvarez Edgardo O, Ruarte Marcela B, Glutamic acid and histamine-sensitive neurons in the ventral hippocampus and the basolateral amygdala of the rat: functional interaction on memory and learning processes, Behavioural Brain Research, 152, 2, 2004. Crossref

  107. Corti Corrado, Crepaldi Luca, Mion Silvia, Roth Adelheid L., Xuereb John H., Ferraguti Francesco, Altered Dimerization of Metabotropic Glutamate Receptor 3 in Schizophrenia, Biological Psychiatry, 62, 7, 2007. Crossref

  108. Okamura Naoe, Hashimoto Kenji, Shimizu Eiji, Koike Kaori, Ohgake Shintaro, Koizumi Hiroki, Kumakiri Chikara, Komatsu Naoya, Iyo Masaomi, Protective effect of LY379268, a selective group II metabotropic glutamate receptor agonist, on dizocilpine-induced neuropathological changes in rat retrosplenial cortex, Brain Research, 992, 1, 2003. Crossref

  109. Stone Trevor W, Inhibitors of the kynurenine pathway, European Journal of Medicinal Chemistry, 35, 2, 2000. Crossref

  110. Breese George R, Knapp Darin J, Moy Sheryl S, Integrative role for serotonergic and glutamatergic receptor mechanisms in the action of NMDA antagonists: potential relationships to antipsychotic drug actions on NMDA antagonist responsiveness, Neuroscience & Biobehavioral Reviews, 26, 4, 2002. Crossref

  111. McAllister K. A. L., Mar A. C., Theobald D. E., Saksida L. M., Bussey T. J., Comparing the effects of subchronic phencyclidine and medial prefrontal cortex dysfunction on cognitive tests relevant to schizophrenia, Psychopharmacology, 232, 21-22, 2015. Crossref

  112. Stone Trevor W, Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection, Trends in Pharmacological Sciences, 21, 4, 2000. Crossref

  113. Nai Qiang, Li Shupeng, Wang Szu-Han, Liu Jing, Lee Frank J.S., Frankland Paul W., Liu Fang, Uncoupling the D1-N-Methyl-D-Aspartate (NMDA) Receptor Complex Promotes NMDA-Dependent Long-Term Potentiation and Working Memory, Biological Psychiatry, 67, 3, 2010. Crossref

  114. Moore Holly, Jentsch J. David, Ghajarnia Mehdi, Geyer Mark A., Grace Anthony A., A Neurobehavioral Systems Analysis of Adult Rats Exposed to Methylazoxymethanol Acetate on E17: Implications for the Neuropathology of Schizophrenia, Biological Psychiatry, 60, 3, 2006. Crossref

  115. Martins-de-Souza Daniel, Schmitt Andrea, Röder Ruth, Lebar Maria, Schneider-Axmann Thomas, Falkai Peter, Turck Christoph W., Sex-specific proteome differences in the anterior cingulate cortex of schizophrenia, Journal of Psychiatric Research, 44, 14, 2010. Crossref

  116. Zuckerman Lee, Weiner Ina, Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring, Journal of Psychiatric Research, 39, 3, 2005. Crossref

  117. Bujas-Bobanovic Maja, Robertson Harold A, Dursun Serdar M, Effects of nitric oxide synthase inhibitor NG-nitro-l-arginine methyl ester on phencyclidine-induced effects in rats, European Journal of Pharmacology, 409, 1, 2000. Crossref

  118. Jardemark K.E, Liang X, Arvanov V, Wang R.Y, Subchronic treatment with either clozapine, olanzapine or haloperidol produces a hyposensitive response of the rat cortical cells to N-methyl-d-aspartate, Neuroscience, 100, 1, 2000. Crossref

  119. Stone Trevor W, Kynurenines in the CNS: from endogenous obscurity to therapeutic importance, Progress in Neurobiology, 64, 2, 2001. Crossref

  120. Eyjolfsson Elvar M., Brenner Eiliv, Kondziella Daniel, Sonnewald Ursula, Repeated injection of MK801: An animal model of schizophrenia?, Neurochemistry International, 48, 6-7, 2006. Crossref

  121. Condray Ruth, Dougherty George G., Keshavan Matcheri S., Reddy Ravinder D., Haas Gretchen L., Montrose Debra M., Matson Wayne R., McEvoy Joseph, Kaddurah-Daouk Rima, Yao Jeffrey K., 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia, The International Journal of Neuropsychopharmacology, 14, 06, 2011. Crossref

  122. Gécz Jozef, Barnett Shaun, Liu Jianjun, Hollway Georgina, Donnelly Andrew, Eyre Helen, Eshkevari Hadi S., Baltazar Romulo, Grunn Adina, Nagaraja Ramaiah, Gilliam Conrad, Peltonen Leena, Sutherland Grant R., Baron Miron, Mulley John C., Characterization of the Human Glutamate Receptor Subunit 3 Gene (GRIA3), a Candidate for Bipolar Disorder and Nonspecific X-Linked Mental Retardation, Genomics, 62, 3, 1999. Crossref

  123. DeLisi Lynn E., A critical overview of recent investigations into the genetics of schizophrenia, Current Opinion in Psychiatry, 12, 1, 1999. Crossref

  124. Levkovitz Yechiel, Levi Uri, Braw Yoram, Cohen Hagit, Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia, Brain Research, 1154, 2007. Crossref

  125. Adams Barbara W., Moghaddam Bita, Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex, Biological Psychiatry, 50, 10, 2001. Crossref

  126. Kim Sang-Young, Lee Hyunseung, Kim Hyun-Ju, Bang Eunjung, Lee Sung-Ho, Lee Do-Wan, Woo Dong-Cheol, Choi Chi-Bong, Hong Kwan Soo, Lee Chulhyun, Choe Bo-Young, In vivoandex vivoevidence for ketamine-induced hyperglutamatergic activity in the cerebral cortex of the rat: Potential relevance to schizophrenia, NMR in Biomedicine, 24, 10, 2011. Crossref

  127. Billingslea Eddie N, Mastropaolo John, Rosse Richard B, Bellack Alan S, Deutsch Stephen I, Interaction of stress and strain on glutamatergic neurotransmission: relevance to schizophrenia, Pharmacology Biochemistry and Behavior, 74, 2, 2003. Crossref

  128. Turgeon Sarah M, Auerbach Eliza A, Duncan-Smith Megan K, George Jonathan R, Graves William W, The Delayed Effects of DTG and MK-801 on Latent Inhibition in a Conditioned Taste-Aversion Paradigm, Pharmacology Biochemistry and Behavior, 66, 3, 2000. Crossref

  129. Steward Lucinda J., Kennedy Matthew D., Morris Brian J., Pratt Judith A., The atypical antipsychotic drug clozapine enhances chronic PCP-induced regulation of prefrontal cortex 5-HT2A receptors, Neuropharmacology, 47, 4, 2004. Crossref

  130. Barbon Alessandro, Fumagalli Fabio, La Via Luca, Caracciolo Luca, Racagni Giorgio, Andrea Riva Marco, Barlati Sergio, Chronic phencyclidine administration reduces the expression and editing of specific glutamate receptors in rat prefrontal cortex, Experimental Neurology, 208, 1, 2007. Crossref

  131. Nudmamud Sutisa, Reynolds Gavin P, Increased density of glutamate/N-methyl-d-aspartate receptors in superior temporal cortex in schizophrenia, Neuroscience Letters, 304, 1-2, 2001. Crossref

  132. Pantazopoulos Harry, Berretta Sabina, In Sickness and in Health: Perineuronal Nets and Synaptic Plasticity in Psychiatric Disorders, Neural Plasticity, 2016, 2016. Crossref

  133. Henson Maile A., Roberts Adam C., Pérez-Otaño Isabel, Philpot Benjamin D., Influence of the NR3A subunit on NMDA receptor functions, Progress in Neurobiology, 91, 1, 2010. Crossref

  134. Jann Michael W., Implications for Atypical Antipsychotics in the Treatment of Schizophrenia: Neurocognition Effects and a Neuroprotective Hypothesis, Pharmacotherapy, 24, 12, 2004. Crossref

  135. Okamura Naoe, Hashimoto Kenji, Kanahara Nobuhisa, Shimizu Eiji, Kumakiri Chikara, Komatsu Naoya, Iyo Masaomi, Protective effect of the antipsychotic drug zotepine on dizocilpine-induced neuropathological changes in rat retrosplenial cortex, European Journal of Pharmacology, 461, 2-3, 2003. Crossref

  136. Selemon Lynn D., Lidow Michael S., Goldman-Rakic Patricia S., Increased volume and glial density in primate prefrontal cortex associated with chronic antipsychotic drug exposure, Biological Psychiatry, 46, 2, 1999. Crossref

  137. Schwarcz Robert, Rassoulpour Arash, Wu Hui-Qiu, Medoff Deborah, Tamminga Carol A, Roberts Rosalinda C, Increased cortical kynurenate content in schizophrenia, Biological Psychiatry, 50, 7, 2001. Crossref

  138. Kubicki M., Park H., Westin C.F., Nestor P.G., Mulkern R.V., Maier S.E., Niznikiewicz M., Connor E.E., Levitt J.J., Frumin M., Kikinis R., Jolesz F.A., McCarley R.W., Shenton M.E., DTI and MTR abnormalities in schizophrenia: Analysis of white matter integrity, NeuroImage, 26, 4, 2005. Crossref

  139. Amitai Nurith, Markou Athina, Effects of metabotropic glutamate receptor 2/3 agonism and antagonism on schizophrenia-like cognitive deficits induced by phencyclidine in rats, European Journal of Pharmacology, 639, 1-3, 2010. Crossref

  140. Homayoun Houman, Moghaddam Bita, Group 5 metabotropic glutamate receptors: Role in modulating cortical activity and relevance to cognition, European Journal of Pharmacology, 639, 1-3, 2010. Crossref

  141. Hashimoto Kenji, Engberg Göran, Shimizu Eiji, Nordin Conny, Lindström Leif H., Iyo Masaomi, Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 29, 5, 2005. Crossref

  142. Stefani Mark R., Moghaddam Bita, Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade, European Journal of Pharmacology, 639, 1-3, 2010. Crossref

  143. Richardson-Burns Sarah M, Haroutunian Vahram, Davis Kenneth L, Watson Stanley J, Meador-Woodruff James H, Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus, Biological Psychiatry, 47, 1, 2000. Crossref

  144. Liu F., Zou X., Sadovova N., Zhang X., Shi L., Guo L., Qian F., Wen Z., Patterson T.A., Hanig J.P., Paule M.G., Slikker W., Wang C., Changes in gene expression after phencyclidine administration in developing rats: a potential animal model for schizophrenia, International Journal of Developmental Neuroscience, 29, 3, 2011. Crossref

  145. Wu Hui-Qiu, Lee Song-Chu, Schwarcz Robert, Systemic administration of 4-chlorokynurenine prevents quinolinate neurotoxicity in the rat hippocampus, European Journal of Pharmacology, 390, 3, 2000. Crossref

  146. Marksteiner J, Weiss U, Weis C, Laslop A, Fischer-Colbrie R, Humpel C, Feldon J, Fleischhacker W.W, Differential regulation of chromogranin A, chromogranin B and secretogranin II in rat brain by phencyclidine treatment, Neuroscience, 104, 2, 2001. Crossref

  147. Sharp Frank R., Hendren Robert L., Psychosis: Atypical limbic epilepsy versus limbic hyperexcitability with onset at puberty?, Epilepsy & Behavior, 10, 4, 2007. Crossref

  148. Mohn Amy R, Gainetdinov Raul R, Caron Marc G, Koller Beverly H, Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia, Cell, 98, 4, 1999. Crossref

  149. Lara D.R., Souza D.O., Schizophrenia: a purinergic hypothesis, Medical Hypotheses, 54, 2, 2000. Crossref

  150. Tomitaka Midori, Tomitaka Shinichiro, Rajdev Sunita, Sharp Frank R, Fluoxetine prevents PCP- and MK801-induced HSP70 expression in injured limbic cortical neurons of rats, Biological Psychiatry, 47, 9, 2000. Crossref

  151. Basińska-Starzycka Anna, Pascual-Marqui Roberto Domingo, Dysfunctional prefrontal attention-related resources in schizophrenia localised by the low-resolution electromagnetic tomography (LORETA), International Congress Series, 1232, 2002. Crossref

  152. Kalinichev Mikhail, Robbins Melanie J., Hartfield Elizabeth M., Maycox Peter R., Moore Susan H., Savage Kevin M., Austin Nigel E., Jones Declan N.C., Comparison between intraperitoneal and subcutaneous phencyclidine administration in Sprague–Dawley rats: A locomotor activity and gene induction study, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 32, 2, 2008. Crossref

  153. Tarazi Frank I., Zhang Kehong, Baldessarini Ross J., Effects of nigrostriatal dopamine denervation on ionotropic glutamate receptors in rat caudate-putamen, Brain Research, 881, 1, 2000. Crossref

  154. John John P., Thirunavukkarasu Priyadarshini, Halahalli Harsha N., Purushottam Meera, Jain Sanjeev, A systematic review of the effect of genes mediating neurodevelopment and neurotransmission on brain morphology: Focus on schizophrenia, Neurology, Psychiatry and Brain Research, 21, 1, 2015. Crossref

  155. Siuciak Judith A., Chapin Douglas S., McCarthy Sheryl A., Guanowsky Victor, Brown Janice, Chiang Phoebe, Marala Ravi, Patterson Terrell, Seymour Patricia A., Swick Andrew, Iredale Philip A., CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity, Neuropharmacology, 52, 2, 2007. Crossref

  156. Gainetdinov Raul R, Mohn Amy R, Caron Marc G, Genetic animal models: focus on schizophrenia, Trends in Neurosciences, 24, 9, 2001. Crossref

  157. Beraki Simret, Kuzmin Alexander, Tai Fadao, Ögren Sven Ove, Repeated low dose of phencyclidine administration impairs spatial learning in mice: Blockade by clozapine but not by haloperidol, European Neuropsychopharmacology, 18, 7, 2008. Crossref

  158. Pritchett David, Jagannath Aarti, Brown Laurence A., Tam Shu K. E., Hasan Sibah, Gatti Silvia, Harrison Paul J., Bannerman David M., Foster Russell G., Peirson Stuart N., Mintz Eric M, Deletion of Metabotropic Glutamate Receptors 2 and 3 (mGlu2 & mGlu3) in Mice Disrupts Sleep and Wheel-Running Activity, and Increases the Sensitivity of the Circadian System to Light, PLOS ONE, 10, 5, 2015. Crossref

  159. Deutsch Stephen I., Rosse Richard B., Schwartz Barbara L., Mastropaolo John, A Revised Excitotoxic Hypothesis of Schizophrenia: Therapeutic Implications, Clinical Neuropharmacology, 24, 1, 2001. Crossref

  160. Bonito-Oliva Alessandra, DuPont Caitlin, Madjid Nather, Ögren Sven Ove, Fisone Gilberto, Involvement of the Striatal Medium Spiny Neurons of the Direct Pathway in the Motor Stimulant Effects of Phencyclidine, International Journal of Neuropsychopharmacology, 2015. Crossref

  161. Martí Sylvia Bort, Cichon Sven, Propping Peter, Nöthen Markus, Human metabotropic glutamate receptor 2 gene (GRM2): Chromosomal sublocalization (3p21.1-p21.2) and genomic organization, American Journal of Medical Genetics, 114, 1, 2002. Crossref

  162. Finamore Terri L., Seybold Kevin S., Noble Michelle, Port Richard L., Contributions of Hippocampal Cellular Damage and NMDA Receptor Dysfunction to Behavioral Markers of Schizophrenia, International Journal of Neuroscience, 109, 1-2, 2001. Crossref

  163. Luoni Alessia, Gass Peter, Brambilla Paolo, Ruggeri Mirella, Riva Marco A., Inta Dragos, Altered expression of schizophrenia-related genes in mice lacking mGlu5 receptors, European Archives of Psychiatry and Clinical Neuroscience, 268, 1, 2018. Crossref

  164. Gallinat Jürgen, McMahon Kibby, Kühn Simone, Schubert Florian, Schaefer Martin, Cross-sectional Study of Glutamate in the Anterior Cingulate and Hippocampus in Schizophrenia, Schizophrenia Bulletin, 42, 2, 2016. Crossref

  165. Matsuzawa Daisuke, Obata Takayuki, Shirayama Yukihiko, Nonaka Hiroi, Kanazawa Yoko, Yoshitome Eiji, Takanashi Junichi, Matsuda Tsuyoshi, Shimizu Eiji, Ikehira Hiroo, Iyo Masaomi, Hashimoto Kenji, Baune Bernhard, Negative Correlation between Brain Glutathione Level and Negative Symptoms in Schizophrenia: A 3T 1H-MRS Study, PLoS ONE, 3, 4, 2008. Crossref

  166. Chen Long, Yang Charles R., Interaction of Dopamine D1 and NMDA Receptors Mediates Acute Clozapine Potentiation of Glutamate EPSPs in Rat Prefrontal Cortex, Journal of Neurophysiology, 87, 5, 2002. Crossref

  167. Honey Rebekah A E, Turner Danielle C, Honey Garry D, Sharar Sam R, Kumaran D, Pomarol-Clotet E, McKenna P, Sahakian B J, Robbins T W, Fletcher P C, Subdissociative Dose Ketamine Produces a Deficit in Manipulation but not Maintenance of the Contents of Working Memory, Neuropsychopharmacology, 28, 11, 2003. Crossref

  168. Cochran Susan M, Kennedy Matthew, McKerchar Clare E, Steward Lucinda J, Pratt Judith A, Morris Brian J, Induction of Metabolic Hypofunction and Neurochemical Deficits after Chronic Intermittent Exposure to Phencyclidine: Differential Modulation by Antipsychotic Drugs, Neuropsychopharmacology, 28, 2, 2003. Crossref

  169. Rassoulpour Arash, Wu Hui-Qiu, Albuquerque Edson X, Schwarcz Robert, Prolonged Nicotine Administration Results in Biphasic, Brain-Specific Changes in Kynurenate Levels in the Rat, Neuropsychopharmacology, 30, 4, 2005. Crossref

  170. Harrison PJ, Lyon L., Sartorius LJ, Burnet Pwj, Lane TA, Review: The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia, Journal of Psychopharmacology, 22, 3, 2008. Crossref

  171. Pratt Judith A, Morris Brian J, The thalamic reticular nucleus: A functional hub for thalamocortical network dysfunction in schizophrenia and a target for drug discovery, Journal of Psychopharmacology, 29, 2, 2015. Crossref

  172. Bray Nicholas J., Preece Anna, Williams Nigel M., Moskvina Valentina, Buckland Paul R., Owen Michael J., O'Donovan Michael C., Haplotypes at the dystrobrevin binding protein 1 (DTNBP1) gene locus mediate risk for schizophrenia through reduced DTNBP1 expression, Human Molecular Genetics, 14, 14, 2005. Crossref

  173. Carfagno Michelle L, Hoskins Lauren A, Pinto Marie E, Yeh Joanne C, Raffa Robert B, Indirect Modulation of Dopamine D2 Receptors as Potential Pharmacotherapy for Schizophrenia: II. Glutamate (Ant)Agonists, Annals of Pharmacotherapy, 34, 6, 2000. Crossref

  174. Tao Rui, Auerbach Sidney B., Regulation of serotonin release by GABA and excitatory amino acids, Journal of Psychopharmacology, 14, 2, 2000. Crossref

  175. Drapalski Amy L., Rosse Richard B., Peebles Roger R., Schwartz Barbara L., Marvel Cherie L., Deutsch Stephen I., Topiramate Improves Deficit Symptoms in a Patient with Schizophrenia when Added to a Stable Regimen of Antipsychotic Medication, Clinical Neuropharmacology, 24, 5, 2001. Crossref

  176. Amitai Nurith, Powell Susan B., Young Jared W., Phencyclidine increased while isolation rearing did not affect progressive ratio responding in rats: Investigating potential models of amotivation in schizophrenia, Behavioural Brain Research, 364, 2019. Crossref

  177. Abdul-Monim Z., Reynolds G. P., Neill J. C., The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat, Journal of Psychopharmacology, 17, 1, 2003. Crossref

  178. Okamura Naoe, Hashimoto Kenji, Shimizu Eiji, Kumakiri Chikara, Komatsu Naoya, Iyo Masaomi, Adenosine A1 Receptor Agonists Block the Neuropathological Changes in Rat Retrosplenial Cortex after Administration of the NMDA Receptor Antagonist Dizocilpine, Neuropsychopharmacology, 29, 3, 2004. Crossref

  179. Chen Long, Muhlhauser Mark, Yang Charles R., Glycine Tranporter-1 Blockade Potentiates NMDA-Mediated Responses in Rat Prefrontal Cortical Neurons In Vitro and In Vivo, Journal of Neurophysiology, 89, 2, 2003. Crossref

  180. Dursun S. M., Deakin J. F. W., Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic caseseries outcome study, Journal of Psychopharmacology, 15, 4, 2001. Crossref

  181. Gadelha Ary, Zugman André, Calzavara Mariana Bendlin, de Mendonça Furtado Remo Holanda, Scorza Fulvio Alexandre, Bressan Rodrigo Afonsecca, Is adenosine associated with sudden death in schizophrenia? A new framework linking the adenosine pathway to risk of sudden death, Neuroscience & Biobehavioral Reviews, 84, 2018. Crossref

  182. Kobayashi Yuka, DNA microarray unravels rapid changes in transcriptome of MK-801 treated rat brain, World Journal of Biological Chemistry, 6, 4, 2015. Crossref

  183. Flores Cecilia, Coyle Joseph T, Regulation of Glutamate Carboxypeptidase II Function in Corticolimbic Regions of Rat Brain by Phencyclidine, Haloperidol, and Clozapine, Neuropsychopharmacology, 28, 7, 2003. Crossref

  184. Takahata Ryuichi, Moghaddam Bita, Activation of Glutamate Neurotransmission in the Prefrontal Cortex Sustains the Motoric and Dopaminergic Effects of Phencyclidine, Neuropsychopharmacology, 28, 6, 2003. Crossref

  185. Kajimoto Yasuo, Shirakawa Osamu, Lin Xian-Hao, Hashimoto Takeshi, Kitamura Noboru, Murakami Naoya, Takumi Toru, Maeda Kiyoshi, Synapse-Associated Protein 90/Postsynaptic Density-95-Associated Protein (SAPAP) is Expressed Differentially in Phencyclidine-Treated Rats and is Increased in the Nucleus Accumbens of Patients with Schizophrenia, Neuropsychopharmacology, 28, 10, 2003. Crossref

  186. Adams Barbara W., Bradberry Charles W., Moghaddam Bita, NMDA antagonist effects on striatal dopamine release: Microdialysis studies in awake monkeys, Synapse, 43, 1, 2002. Crossref

  187. Jardemark Kent E., Ai Jinglu, Ninan Ipe, Wang Rex Y., Biphasic modulation of NMDA-induced responses in pyramidal cells of the medial prefrontal cortex by Y-931, a potential atypical antipsychotic drug, Synapse, 41, 4, 2001. Crossref

  188. Honey R A E, Honey G D, O'Loughlin C, Sharar S R, Kumaran D, Bullmore E T, Menon D K, Donovan T, Lupson V C, Bisbrown-Chippendale R, Fletcher P C, Acute Ketamine Administration Alters the Brain Responses to Executive Demands in a Verbal Working Memory Task: an fMRI Study, Neuropsychopharmacology, 29, 6, 2004. Crossref

  189. Sun Min-Yu, Izumi Yukitoshi, Benz Ann, Zorumski Charles F., Mennerick Steven, Endogenous 24S-hydroxycholesterol modulates NMDAR-mediated function in hippocampal slices, Journal of Neurophysiology, 115, 3, 2016. Crossref

  190. Tajiri Koji, Emori Kenji, Murata Masahiko, Tanaka Kodai, Suzuki Michio, Uehara Takashi, Sumiyoshi Tomiki, Ashby Charles R., Kurachi Masayoshi, Intracerebroventricular administration of NMDA-R1 antisense oligodeoxynucleotide significantly alters the activity of ventral tegmental area dopamine neurons: An electrophysiological study, Synapse, 40, 4, 2001. Crossref

  191. Kavalali Ege T., Synaptic Vesicle Reuse and Its Implications, The Neuroscientist, 12, 1, 2006. Crossref

  192. Homayoun Houman, Stefani Mark R, Adams Barbara W, Tamagan Gilles D, Moghaddam Bita, Functional Interaction Between NMDA and mGlu5 Receptors: Effects on Working Memory, Instrumental Learning, Motor Behaviors, and Dopamine Release, Neuropsychopharmacology, 29, 7, 2004. Crossref

  193. Harrison Paul J., The neuropathology of schizophrenia, Brain, 122, 4, 1999. Crossref

  194. Deutsch Stephen I., Schwartz Barbara L., Rosse Richard B., Mastropaolo John, Marvel Cherie L., Drapalski Amy L., Adjuvant Topiramate Administration: A Pharmacologic Strategy for Addressing NMDA Receptor Hypofunction in Schizophrenia, Clinical Neuropharmacology, 26, 4, 2003. Crossref

  195. Wood Christian M., Wafford Keith A., McCarthy Andrew P., Hewes Nicola, Shanks Elaine, Lodge David, Robinson Emma S.J., Investigating the role of mGluR2 versus mGluR3 in antipsychotic-like effects, sleep-wake architecture and network oscillatory activity using novel Han Wistar rats lacking mGluR2 expression, Neuropharmacology, 140, 2018. Crossref

  196. Tsapakis Eva M., Travis Michael J., Glutamate and psychiatric disorders, Advances in Psychiatric Treatment, 8, 3, 2002. Crossref

  197. Tamminga Carol, Glutamatergic aspects of schizophrenia, British Journal of Psychiatry, 174, S37, 1999. Crossref

  198. Bhriain S. Ni, Clare A. W., Lawlor B. A., Neuroimaging: a new training issue in psychiatry?, Psychiatric Bulletin, 29, 5, 2005. Crossref

  199. Burk Joshua A., Blumenthal Sarah A., Maness Eden B., Neuropharmacology of attention, European Journal of Pharmacology, 835, 2018. Crossref

  200. Murphy Emily R., Dalley Jeffrey W., Robbins Trevor W., Local glutamate receptor antagonism in the rat prefrontal cortex disrupts response inhibition in a visuospatial attentional task, Psychopharmacology, 179, 1, 2005. Crossref

  201. Le Corre Sylvie, Harper Clive G., Lopez Pilar, Ward Philip, Catts Stanley, Increased levels of expression of an NMDAR1 splice variant in the superior temporal gyrus in schizophrenia, NeuroReport, 11, 5, 2000. Crossref

  202. Thaker Gunvant K., Carpenter William T., Advances in schizophrenia, Nature Medicine, 7, 6, 2001. Crossref

  203. Cochran Susan M., Fujimura Masatake, Morris Brian J., Pratt Judith A., Acute and delayed effects of phencyclidine upon mRNA levels of markers of glutamatergic and GABAergic neurotransmitter function in the rat brain, Synapse, 46, 3, 2002. Crossref

  204. Marek Gerard J., Behl Berthold, Bespalov Anton Y., Gross Gerhard, Lee Younglim, Schoemaker Hans, Glutamatergic (N-Methyl-d-aspartate Receptor) Hypofrontality in Schizophrenia: Too Little Juice or a Miswired Brain?, Molecular Pharmacology, 77, 3, 2010. Crossref

  205. Matveeva Tatyana M., Pisansky Marc T., Young Amy, Miller Robert F., Gewirtz Jonathan C., Sociality deficits in serine racemase knockout mice, Brain and Behavior, 9, 10, 2019. Crossref

  206. Auerbach Sidney B., Regulation of serotonin release by inhibitory and excitatory amino acids, in Serotonin and Sleep: Molecular, Functional and Clinical Aspects, 2008. Crossref

  207. Tamminga C. A., Lahti A. C., Medoff D. R., Holcomb H. H., Die funktionelle Beteiligung des vorderen zingulären Kortex an der schizophrenen Psychose, in Psychiatrie der Gegenwart 5, 2000. Crossref

  208. Lieberman Jeffrey A., Bymaster Frank P., Meltzer Herbert Y., Deutch Ariel Y., Duncan Gary E., Marx Christine E., Aprille June R., Dwyer Donard S., Li Xin-Min, Mahadik Sahebarao P., Duman Ronald S., Porter Joseph H., Modica-Napolitano Josephine S., Newton Samuel S., Csernansky John G., Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection, Pharmacological Reviews, 60, 3, 2008. Crossref

  209. Klivényi Péter, Toldi József, Vécsei László, Kynurenines in Neurodegenerative Disorders: Therapeutic Consideration, in Frontiers in Clinical Neuroscience, 541, 2004. Crossref

  210. Wolf R., Pharmakologische Beeinflussbarkeit von Verhaltensparametern in genetischen und Läsions-induzierten Tiermodellen der Schizophrenie, in Universitätskolloquien zur Schizophrenie, 2004. Crossref

  211. Chen Yue, Spatial integration in perception and cognition: An empirical approach to the pathophysiology of schizophrenia, Behavioral and Brain Sciences, 26, 1, 2003. Crossref

  212. Condray Ruth, Steinhauer Stuart R., Mechanisms of disrupted language comprehension in schizophrenia, Behavioral and Brain Sciences, 26, 1, 2003. Crossref

  213. Xia Zongqi, Sheffler Douglas J., Roth Bryan L., 5-HT Receptor-Associated Proteins (FRAPs), in The Serotonin Receptors, 2006. Crossref

  214. Bressler Steven L., Context rules, Behavioral and Brain Sciences, 26, 1, 2003. Crossref

  215. Kiss C., Vécsei L., Kynurenines in the Brain: Preclinical and Clinical Studies, Therapeutic Considerations, in Handbook of Neurochemistry and Molecular Neurobiology, 2009. Crossref

  216. Barendregt Hendrik Pieter, A wide-spectrum coordination model of schizophrenia, Behavioral and Brain Sciences, 26, 1, 2003. Crossref

  217. Barch Deanna M., Braver Todd S., Where the rubber meets the road: The importance of implementation, Behavioral and Brain Sciences, 26, 1, 2003. Crossref

  218. Alpert Murray, Angrist Burt, The ketamine model for schizophrenia, Behavioral and Brain Sciences, 26, 1, 2003. Crossref

  219. Arai Amy C., Xia Yan-Fang, Kessler Markus, Phillips Dean, Chamberlin Richard, Granger Richard, Lynch Gary, Effects of 5′-Alkyl-Benzothiadiazides on (R,S)-α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Biophysics and Synaptic Responses, Molecular Pharmacology, 62, 3, 2002. Crossref

  220. Histology, in The Brain and Behavior, 2005. Crossref

  221. Hemsley David R., Schizophrenic cognition: Taken out of context?, Behavioral and Brain Sciences, 26, 1, 2003. Crossref

  222. Limbic system: temporal lobe, in The Brain and Behavior, 2005. Crossref

  223. Grossberg Stephen, Linking brain to mind in normal behavior and schizophrenia, Behavioral and Brain Sciences, 26, 1, 2003. Crossref

  224. Limbic system: overview, in The Brain and Behavior, 2005. Crossref

  225. Gooding Diane C., Braun Jacqueline G., Cognitive coordination deficits: A necessary but not sufficient factor in the development of schizophrenia, Behavioral and Brain Sciences, 26, 1, 2003. Crossref

  226. Enomoto Takeshi, Noda Yukihiro, Mouri Akihiro, Shin Eun-Joo, Wang Dayong, Murai Rina, Hotta Kazuo, Furukawa Hiroshi, Nitta Atsumi, Kim Hyoung-Chun, Nabeshima Toshitaka, Long-Lasting Impairment of Associative Learning Is Correlated with a Dysfunction of N-Methyl-d-aspartate-Extracellular Signaling-Regulated Kinase Signaling in Mice after Withdrawal from Repeated Administration of Phencyclidine, Molecular Pharmacology, 68, 6, 2005. Crossref

  227. Suzuki Katsuaki, Nakamura Kazuhiko, Iwata Yasuhide, Sekine Yoshimoto, Kawai Masayoshi, Sugihara Genichi, Tsuchiya Kenji J., Suda Shiro, Matsuzaki Hideo, Takei Nori, Hashimoto Kenji, Mori Norio, Decreased expression of reelin receptor VLDLR in peripheral lymphocytes of drug-naive schizophrenic patients, Schizophrenia Research, 98, 1-3, 2008. Crossref

  228. Ginsberg J. P., Setting domain boundaries for convergence of biological and psychological perspectives on cognitive coordination in schizophrenia, Behavioral and Brain Sciences, 26, 1, 2003. Crossref

  229. Alves Óscar L., Bullock Ross, Excitotoxic Damage in Traumatic Brain Injury, in Brain Injury, 2001. Crossref

  230. Skaper Stephen D., Phosphatidylinositol 3-Kinase/Glycogen Synthase Kinase and Mitogen-Activated Protein Kinase Signalling Cascades in Neuronal Cell Survival: What the Neurotrophins Have Taught Us and Implications For Neuropsychiatric Disorders, in Brain Protection in Schizophrenia, Mood and Cognitive Disorders, 2010. Crossref

  231. Ganel R., Rothstein J. D., Glutamate Transporter Dysfunction and Neuronal Death, in Ionotropic Glutamate Receptors in the CNS, 141, 1999. Crossref

  232. Kristiansen L. V., Cowell R. M., Biscaia M., McCullumsmith R. E., Meador-Woodruff J. H., Alterations of Neurotransmitter Receptors in Schizophrenia: Evidence from Postmortem Studies, in Handbook of Neurochemistry and Molecular Neurobiology, 2009. Crossref

  233. Tagamets M.-A., Horwitz Barry, Synchronous dynamics for cognitive coordination: But how?, Behavioral and Brain Sciences, 26, 1, 2003. Crossref

  234. Strelets Valeria, Cortical connectivity in high-frequency beta-rhythm in schizophrenics with positive and negative symptoms, Behavioral and Brain Sciences, 26, 1, 2003. Crossref

  235. Sass Louis A., Uhlhaas Peter J., Phenomenology, context, and self-experience in schizophrenia, Behavioral and Brain Sciences, 26, 1, 2003. Crossref

  236. Sanders Glenn S., Platek Steven M., Gallup Gordon G., No blind schizophrenics: Are NMDA-receptor dynamics involved?, Behavioral and Brain Sciences, 26, 1, 2003. Crossref

  237. Guitart Xavier, σ Receptors and Scizophrenia, in Sigma Receptors, 2007. Crossref

  238. Stevens Janice R., Schizophrenia: developmental, degenerative or both?, in Search for the Causes of Schizophrenia, 2004. Crossref

  239. Young Jared W., Zhou Xianjin, Geyer Mark A., Animal Models of Schizophrenia, in Behavioral Neurobiology of Schizophrenia and Its Treatment, 4, 2010. Crossref

  240. Silverstein Steven M., Phillips William A., Cognitive coordination and its neurobiological bases: A new continent to explore, Behavioral and Brain Sciences, 26, 1, 2003. Crossref

  241. Williams Leanne M., Lee Kwang-Hyuk, Haig Albert, Gordon Evian, High-frequency synchronisation in schizophrenia: Too much or too little?, Behavioral and Brain Sciences, 26, 1, 2003. Crossref

  242. Titone Debra, Debruille J. Bruno, Guarding against over-inclusive notions of “context”: Psycholinguistic and electrophysiological studies of specific context functions in schizophrenia, Behavioral and Brain Sciences, 26, 1, 2003. Crossref

  243. Jane D. E., Tse H. W., Skifter D. A., Christie J. M., Monaghan D. T., Glutamate Receptor Ion Channels: Activators and Inhibitors, in Pharmacology of Ionic Channel Function: Activators and Inhibitors, 147, 2000. Crossref

  244. Talamini L. M., Meeter M., Murre J. M. J., Combating fuzziness with computational modeling, Behavioral and Brain Sciences, 26, 1, 2003. Crossref

  245. MacDonald Angus W., Reconciling schizophrenic deficits in top-down and bottom-up processes: Not yet, Behavioral and Brain Sciences, 26, 1, 2003. Crossref

  246. Leiser David, Bonshtein Udi, Theory of mind in schizophrenia: Damaged module or deficit in cognitive coordination?, Behavioral and Brain Sciences, 26, 1, 2003. Crossref

  247. Hayashi Teruo, Su Tsung-Ping, ??-1 Receptor Ligands, CNS Drugs, 18, 5, 2004. Crossref

  248. Kindlundh-Högberg Anna MS, Blomqvist Anna, Malki Rana, Schiöth Helgi B, Extensive neuroadaptive changes in cortical gene-transcript expressions of the glutamate system in response to repeated intermittent MDMA administration in adolescent rats, BMC Neuroscience, 9, 1, 2008. Crossref

  249. Kisley Michael A., Davalos Deana B., Is sensory gating a form of cognitive coordination?, Behavioral and Brain Sciences, 26, 1, 2003. Crossref

  250. Javitt Daniel C., Peeling the onion: NMDA dysfunction as a unifying model in schizophrenia, Behavioral and Brain Sciences, 26, 1, 2003. Crossref

  251. Hoffman Ralph E., McGlashan Thomas H., NMDA-receptor hypofunction versus excessive synaptic elimination as models of schizophrenia, Behavioral and Brain Sciences, 26, 1, 2003. Crossref

  252. Roelfsema Pieter R., Supèr Hans, Why do schizophrenic patients hallucinate?, Behavioral and Brain Sciences, 26, 1, 2003. Crossref

  253. Raffone Antonino, Murre Jaap M. J., Wolters Gezinus, NMDA synapses can bias competition between object representations and mediate attentional selection, Behavioral and Brain Sciences, 26, 1, 2003. Crossref

  254. Pflieger Mark E., Inferring contextual field interactions from scalp EEG, Behavioral and Brain Sciences, 26, 1, 2003. Crossref

  255. Park Sohee, Lee Junghee, Folley Bradley, Kim Jejoong, Schizophrenia: Putting context in context, Behavioral and Brain Sciences, 26, 1, 2003. Crossref

  256. Gareri Pietro, De Fazio Pasquale, Stilo Mariagrazia, Ferreri Guido, De Sarro Giovambattista, Conventional and Atypical Antipsychotics in the Elderly, Clinical Drug Investigation, 23, 5, 2003. Crossref

  257. Oades Robert D., Röpcke Bernd, Oknina Ljubov, Context, connection, and coordination: The need to switch, Behavioral and Brain Sciences, 26, 1, 2003. Crossref

  258. Mendoza John E., Foundas Anne L., Neurochemical Transmission, in Clinical Neuroanatomy: A Neurobehavioral Approach, 2008. Crossref

  259. Tamminga Carol A., Medoff Deborah C., Thaker Gunvant, Schizophrenia, in Principles of Molecular Medicine, 2006. Crossref

  260. Benes Francine M., Berretta Sabina, Defining the Role of Specific Limbic Circuitry in the Pathophysiology of Schizophrenia and Bipolar Disorder, in The Postmortem Brain in Psychiatric Research, 4, 2002. Crossref

  261. Kemp John A., McKernan Ruth M., NMDA receptor pathways as drug targets, Nature Neuroscience, 5, S11, 2002. Crossref

  262. Tamminga C. A., Lahti A. C., Medoff D. R., Holcomb H. H., The Functional Involvement of the Anterior Cingulate Cortex in Schizophrenic Psychosis, in Contemporary Psychiatry, 2001. Crossref

  263. Atkinson B. N., Bell S. C., De Vivo M., Kowalski L. R., Lechner S. M., Ognyanov V. I., Tham C.-S., Tsai C., Jia J., Ashton D., Klitenick M. A., ALX 5407: A Potent, Selective Inhibitor of the hGlyT1 Glycine Transporter, Molecular Pharmacology, 60, 6, 2001. Crossref

  264. Keshavan Matcheri S., Cornblatt Barbara A., Developmental models and hypothesis-driven early interventions in schizophrenia, in Neurodevelopment and Schizophrenia, 2004. Crossref

  265. Wang Jing, Yu Wenwen, Gao Qin, Ju Chuanxia, Wang KeWei, Prefrontal inhibition of neuronal K v 7 channels enhances prepulse inhibition of acoustic startle reflex and resistance to hypofrontality , British Journal of Pharmacology, 177, 20, 2020. Crossref

  266. Nawaz Rukhsana, Gul Saima, Amin Rafat, Huma Tanzeel, Al Mughairbi Fadwa, Overview of schizophrenia research and treatment in Pakistan, Heliyon, 6, 11, 2020. Crossref

  267. Cioffi Christopher L., Liu Shuang, Wolf Mark A., Guzzo Peter R., Sadalapure Kashinath, Parthasarathy Visweswaran, Loong David T. J., Maeng Jun-Ho, Carulli Edmund, Fang Xiao, Karunakaran Kalesh, Matta Lakshman, Choo Sok Hui, Panduga Shailijia, Buckle Ronald N., Davis Randall N., Sakwa Samuel A., Gupta Priya, Sargent Bruce J., Moore Nicholas A., Luche Michele M., Carr Grant J., Khmelnitsky Yuri L., Ismail Jiffry, Chung Mark, Bai Mei, Leong Wei Yee, Sachdev Nidhi, Swaminathan Srividya, Mhyre Andrew J., Synthesis and Biological Evaluation ofN-((1-(4-(Sulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide Inhibitors of Glycine Transporter-1, Journal of Medicinal Chemistry, 59, 18, 2016. Crossref

  268. Schauz Cornelia, Koch Michael, Blockade of NMDA Receptors in the Amygdala Prevents Latent Inhibition of Fear-Conditioning, Learning & Memory, 7, 6, 2000. Crossref

  269. Han Zhengrong, Chai Weitai, Wang Zhuo, Xiao Fangyan, Dai Jiapei, Quantum energy levels of glutamate modulate neural biophotonic signals, Photochemical & Photobiological Sciences, 20, 3, 2021. Crossref

  270. Tanra Andi Jayalangkara, Sabaruddin Herwina, Liaury Kristian , Zainuddin Andi Alfian , Effect of Adjuvant Vitamin C on Brain-Derived Neurotrophic Factor Levels and Improvement of Negative Symptoms in Schizophrenic Patients, Open Access Macedonian Journal of Medical Sciences, 9, T3, 2021. Crossref

  271. Moon Sun-Young, Kim Minah, Lho Silvia Kyungjin, Oh Sanghoon, Kim Se Hyun, Kwon Jun Soo, Systematic Review of the Neural Effect of Electroconvulsive Therapy in Patients with Schizophrenia: Hippocampus and Insula as the Key Regions of Modulation, Psychiatry Investigation, 18, 6, 2021. Crossref

  272. Stone Trevor W., Relationships and Interactions between Ionotropic Glutamate Receptors and Nicotinic Receptors in the CNS, Neuroscience, 468, 2021. Crossref

  273. Bräuner-Osborne Hans, Egebjerg Jan, Nielsen Elsebet Ø., Madsen Ulf, Krogsgaard-Larsen Povl, Ligands for Glutamate Receptors:  Design and Therapeutic Prospects, Journal of Medicinal Chemistry, 43, 14, 2000. Crossref

  274. Rammsayer Thomas H., Effects of Pharmacologically Induced Changes in NMDA-Receptor Activity on Long-Term Memory in Humans, Learning & Memory, 8, 1, 2001. Crossref

  275. Ibrahim Hisham M., Tamminga Carol A., Schizophrenia: Treatment Targets Beyond Monoamine Systems, Annual Review of Pharmacology and Toxicology, 51, 1, 2011. Crossref

  276. Wesseling Hendrik, Guest Paul C, Lee Chi-Ming, Wong Erik HF, Rahmoune Hassan, Bahn Sabine, Integrative proteomic analysis of the NMDA NR1 knockdown mouse model reveals effects on central and peripheral pathways associated with schizophrenia and autism spectrum disorders, Molecular Autism, 5, 1, 2014. Crossref

  277. Liao Lujian, Sando Richard C., Farnum John B., Vanderklish Peter W., Maximov Anton, Yates John R., 15N-Labeled Brain Enables Quantification of Proteome and Phosphoproteome in Cultured Primary Neurons, Journal of Proteome Research, 11, 2, 2012. Crossref

  278. Rowley Michael, Bristow Linda J., Hutson Peter H., Current and Novel Approaches to the Drug Treatment of Schizophrenia, Journal of Medicinal Chemistry, 44, 4, 2001. Crossref

  279. Moghaddam Bita, Adams Barbara W., Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats, Science, 281, 5381, 1998. Crossref

  280. Nilsson L. K., Linderholm K. R., Erhardt S., Subchronic treatment with kynurenine and probenecid: effects on prepulse inhibition and firing of midbrain dopamine neurons, Journal of Neural Transmission, 113, 5, 2006. Crossref

  281. Hashimoto Kenji, Sawa Akira, Iyo Masaomi, Increased Levels of Glutamate in Brains from Patients with Mood Disorders, Biological Psychiatry, 62, 11, 2007. Crossref

  282. Harrison P J, Weinberger D R, Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence, Molecular Psychiatry, 10, 1, 2005. Crossref

  283. Harrison Paul J., Postmortem studies in schizophrenia, Dialogues in Clinical Neuroscience, 2, 4, 2000. Crossref

  284. Abi-Dargham Anissa, Rodenhiser Janine, Printz David, Zea-Ponce Yolanda, Gil Roberto, Kegeles Lawrence S., Weiss Richard, Cooper Thomas B., Mann J. John, Van Heertum Ronald L., Gorman Jack M., Laruelle Marc, Increased baseline occupancy of D 2 receptors by dopamine in schizophrenia , Proceedings of the National Academy of Sciences, 97, 14, 2000. Crossref

  285. Wang Ya-Nan, Figueiredo Dwight, Sun Xiang-Dong, Dong Zhao-Qi, Chen Wen-Bing, Cui Wan-Peng, Liu Fang, Wang Hong-Sheng, Li Hai-Wen, Robinson Heath, Fei Er-Kang, Pan Bing-Xing, Li Bao-Ming, Xiong Wen-Cheng, Mei Lin, Controlling of glutamate release by neuregulin3 via inhibiting the assembly of the SNARE complex, Proceedings of the National Academy of Sciences, 115, 10, 2018. Crossref

  286. Histology, in The Brain and Behavior, 2010. Crossref

  287. Linn Gary S., O’Keeffe Robert T., Lifshitz Kenneth, Schroeder Charles, Javitt Daniel C., Behavioral effects of orally administered glycine in socially housed monkeys chronically treated with phencyclidine, Psychopharmacology, 192, 1, 2007. Crossref

  288. Limbic system: Temporal lobe, in The Brain and Behavior, 2010. Crossref

  289. Limbic system: Overview, in The Brain and Behavior, 2010. Crossref

  290. Marek Gerard J., Kinon Bruce J., McKinzie David L., Schkeryantz Jeffrey M., Monn James A., Metabotropic Glutamate 2/3 Receptor Agonists and Positive Allosteric Modulators of Metabotropic Glutamate Receptor 2 as Novel Agents for the Treatment of Schizophrenia, in Targets and Emerging Therapies for Schizophrenia, 2012. Crossref

  291. Scott Lena, Kruse Maria Sol, Forssberg Hans, Brismar Hjalmar, Greengard Paul, Aperia Anita, Selective up-regulation of dopamine D1 receptors in dendritic spines by NMDA receptor activation, Proceedings of the National Academy of Sciences, 99, 3, 2002. Crossref

  292. Siuciak Judith A., Chapin Douglas S., McCarthy Sheryl A., Martin Ashley N., Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme, Psychopharmacology, 192, 3, 2007. Crossref

  293. Arranz M J, de Leon J, Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research, Molecular Psychiatry, 12, 8, 2007. Crossref

  294. Shinozaki Naoko, Yabe Hirooki, Sato Yasuharu, Hiruma Tomiharu, Sutoh Takeyuki, Nashida Tadayoshi, Matsuoka Takashi, Kaneko Sunao, The difference in Mismatch negativity between the acute and post-acute phase of schizophrenia, Biological Psychology, 59, 2, 2002. Crossref

  295. Kapur S, Seeman P, NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2 receptors—implications for models of schizophrenia, Molecular Psychiatry, 7, 8, 2002. Crossref

  296. Weiner Ina, Arad Michal, The pharmacology of latent inhibition and its relevance to schizophrenia, in Latent Inhibition, 2010. Crossref

  297. Rice S R, Niu N, Berman D B, Heston L L, Sobell J L, Identification of single nucleotide polymorphisms (SNPs) and other sequence changes and estimation of nucleotide diversity in coding and flanking regions of the NMDAR1 receptor gene in schizophrenic patients, Molecular Psychiatry, 6, 3, 2001. Crossref

Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen Preise und Aborichtlinien Begell House Kontakt Language English 中文 Русский Português German French Spain